Search Result
Results for "
mononuclear+cell
" in MedChemExpress (MCE) Product Catalog:
4
Biochemical Assay Reagents
3
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-P10587
-
|
JNJ-77242113; JNJ-2113; PN-235
|
Interleukin Related
STAT
IFNAR
|
Inflammation/Immunology
|
|
Icotrokinra (JNJ-77242113) is an orally available, selective antagonist of the IL-23 receptor. Icotrokinra inhibits IL-23-induced STAT3 phosphorylation in peripheral blood mononuclear cells (IC50=5.6 pM) and inhibits IL-23-induced interferon IFN-γ production in NK cells with an IC50 of 18.4 pM. Icotrokinra exhibits anti-inflammatory activity in a rat TNBS-induced colitis model. Icotrokinra can be used in the study of psoriasis, psoriatic arthritis, and inflammatory bowel disease .
|
-
-
- HY-13238
-
Dolutegravir
Maximum Cited Publications
32 Publications Verification
S/GSK1349572
|
HIV Integrase
HIV
|
Infection
|
|
Dolutegravir (S/GSK1349572) is a highly potent and orally bioavailable HIV integrase strand transfer inhibitor with an IC50 of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir (S/GSK1349572) inhibits HIV-1 viral replication with an IC50 of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC50=3.6-5.8 nM) .
|
-
-
- HY-100870
-
|
ABX464
|
HIV
|
Infection
|
|
Obefazimod (ABX464) is a potent anti-HIV agent. Obefazimod inhibits HIV-1 replication in stimulated peripheral blood mononuclear cells (PBMCs) with an IC50 ranging between 0.1 μM and 0.5 μM.
|
-
-
- HY-103697
-
|
|
Toll-like Receptor (TLR)
|
Cancer
|
|
Gardiquimod is an imidazoline TLR7/8 agonist. Gardiquimod inhibits HIV-1 infection of macrophages and activated peripheral blood mononuclear cells (PBMCs). Gardiquimod specifically activates TLR7 at concentrations below 10 μM.
|
-
-
- HY-P3160C
-
|
|
Biochemical Assay Reagents
|
Infection
|
|
Fibronectin, bovine plasma is a fibronectin derived from bovine plasma. Fibronectin is an extracellular matrix protein that is upregulated and essential in many developmental processes, and also exists in the pathological progression of tissues and wound healing. Fibronectin specifically binds to a large number of molecules, including other components of the extracellular matrix, signaling molecules and cell adhesion molecules. The interaction between cells and fibronectin leads to bidirectional crosstalk, which regulates cell functions and induces cell-dependent changes in the extracellular matrix. Fibronectin, bovine plasma inhibits the production of bovine leukemia virus (BLV) p24 core protein in naturally infected bovine peripheral blood mononuclear cells .
|
-
-
- HY-13238A
-
|
S/GSK1349572 sodium
|
HIV Integrase
HIV
|
Infection
|
|
Dolutegravir sodium (S/GSK1349572 sodium) is a highly potent and orally bioavailable HIV integrase strand transfer inhibitor with an IC50 of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir sodium (S/GSK1349572 sodium) inhibits HIV-1 viral replication with an IC50 of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir sodium (S/GSK1349572 sodium) retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC50=3.6-5.8 nM) .
|
-
-
- HY-B0439
-
|
Sulphadoxine
|
Parasite
HIV
Antibiotic
Endogenous Metabolite
|
Infection
|
|
Sulfadoxine(Sulphadoxine) is a long acting sulfonamide that is used, usually in combination with other agents, for respiratory, urinary tract and malarial infections. Sulfadoxine inhibits HIV replication in peripheral blood mononuclear cells.
|
-
-
- HY-129460
-
|
|
Reactive Oxygen Species (ROS)
|
Neurological Disease
|
|
XJB-5-131 is a mitochondria-targeted ROS and electron scavenger . XJB-5-131 is a bi-functional antioxidant that comprises a radical scavenger. XJB-5-131 is a synthetic antioxidant that targets mitochondria . XJB-5-131 is an effective ionizing irradiation protector and mitigator of cord blood mononuclear cells (CB MNCs) .
|
-
-
- HY-138568
-
|
|
MAP4K
|
Inflammation/Immunology
|
|
HPK1-IN-3 is a potent and selective ATP-competitive hematopoietic progenitor kinase 1 (HPK1; MAP4K1) inhibitor with an IC50 of 0.25 nM. HPK1-IN-3 has IL-2 cellular potency with an EC50 of 108 nM in human peripheral blood mononuclear cells (PBMCs) .
|
-
-
- HY-P99943
-
|
KN-046
|
PD-1/PD-L1
CTLA-4
|
Cancer
|
|
Erfonrilimab (KN-046) is a monoclonal antibody targeting PD-L1/CTLA-4. Erfonrilimab blocks the PD-L1 and CTLA-4 pathways, thereby regulating T cell function. Erfonrilimab enhances the secretion of IL-2 in superantigen-stimulated peripheral blood mononuclear cells. Erfonrilimab inhibits tumor growth in xenograft and double gene knock-in mouse models. Erfonrilimab can be used in research related to a variety of advanced solid tumors, including non-small cell lung cancer and nasopharyngeal carcinoma.
|
-
-
- HY-155175
-
|
|
Tim3
IFNAR
|
Cancer
|
|
TIM-3-IN-2 is a TIM-3 inhibitor. TIM-3-IN-2 blocks the interactions of TIM-3 with PtdSer, CEACAM1 and Gal-9, and inhibits the immunosuppressive function of TIM-3. TIM-3-IN-2 restores IFNγ release from peripheral blood mononuclear cells. TIM-3-IN-2 inhibits the proliferation of acute myeloid leukemia cells. TIM-3-IN-2 can be used for the research of acute myeloid leukemia .
|
-
-
- HY-113953
-
|
|
Caspase
Apoptosis
|
Inflammation/Immunology
|
|
Z-Asp-CH2-DCB is an irreversible broad spectrum caspase inhibitor. Z-Asp-CH2-DCB also inhibits proteases with caspase-like activity. Z-D-CH2-DCB blocks the production of IL-1β, TNF-α, IL-6, and IFN-γ in staphylococcal enterotoxin B (SEB)-stimulated peripheral blood mononuclear cells (PBMC), and reduces SEB-1-stimulated T-cell proliferation in a dose-dependent manner. Z-Asp-CH2-DCB prevents SU5416-induced septal cell apoptosis and emphysema development .
|
-
-
- HY-177338
-
|
|
STING
Cyclic GMP-AMP Synthase
IFNAR
TNF Receptor
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
STING agonist-45 is a selective STING agonist (EC50 = 0.28 μM). STING agonist-45 activates the innate immune response through the cGAS-STING pathway, upregulating key markers such as p-TBK1 and IRF3. STING agonist-45 exhibits robust STING activation in human peripheral blood mononuclear cells (PBMCs), inducing the production of type I interferons (such as IFN-β) and downstream cytokines (such as TNF-α and IL-6). STING agonist-45 enhances anti-tumor immunity, inhibits tumor growth, and increases CD8 + T cell infiltration in mouse models. STING agonist-45 is promising for the study of STING-related diseases .
|
-
-
- HY-B0392
-
-
-
- HY-156961
-
|
GLPG3667
|
JAK
|
Inflammation/Immunology
|
|
Cadefrecitinib (GLPG3667) is a reversible, ATP-competitive and orally active TYK2 inhibitor with an IC50 of 2.3 nM. Cadefrecitinib inhibits IFNα/pSTAT1, and the IC50 values in human peripheral blood mononuclear cell (PBMC) and whole blood assays are 70 nM and 623 nM, respectively. Cadefrecitinib has the potential for the study of inflammatory and autoimmune diseases .
|
-
-
- HY-13224
-
|
|
Kinesin
Apoptosis
Mitosis
|
Cancer
|
|
AZD4877 is another isostere to Ispinesib (HY-50759)and also a kinesin spindle protein (Eg5) inhibitor with IC50 of 2 nM.AZD4877 arrests cell mitosis, leads to the formation of the monopolar spindle phenotype and induces apoptosis. AZD4877 inhibits circulating peripheral blood mononuclear cells (PBMCs) and has anti-cancer activity .
|
-
-
- HY-142989
-
|
|
Liposome
HIV
HCV
HBV
|
Infection
Cancer
|
|
1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine is a polyunsaturated phospholipid that serves as a component of lipid monolayers and small unilamellar vesicles. 1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine can be used to prepare endoplasmic reticulum-targeted liposomes (PERLs), which are composed of 1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine, l-α-phosphatidylinositol and l-α-phosphatidylserine at a molar ratio of 1.5:1.5:1:1. PERLs reduce cholesterol levels in human peripheral blood mononuclear cells (PBMCs) and decrease HIV-1 particle secretion from HIV-1-infected PBMCs. Liposomes formed from 1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine exhibit cytotoxicity against leukemia cells. 1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine is applicable to studies related to hepatitis C virus infection, HIV infection, hepatitis B virus infection and leukemia .
|
-
-
- HY-B0902A
-
|
MF-934 hydrochloride
|
Bacterial
Antibiotic
|
Infection
|
|
Rufloxacin hydrochloride (MF-934 hydrochloride) is a fluoroquinolone antibacterial, inhibits B-cell differentiation in human mononuclear cells, inhibits Topo.
|
-
-
- HY-103697A
-
|
|
Toll-like Receptor (TLR)
|
Cancer
|
|
Gardiquimod diTFA is an imidazoline TLR7/8 agonist. Gardiquimod diTFA inhibits HIV-1 infection of macrophages and activated peripheral blood mononuclear cells (PBMCs). Gardiquimod diTFA specifically activates TLR7 at concentrations below 10 μM.
|
-
-
- HY-155782
-
|
|
RIP kinase
|
Inflammation/Immunology
|
|
Zharp2-1 is an oral effective RIPK2 inhibitor, highly associated with inflammatory bowel disease (IBD). Zharp2-1 blocker muramyl dipeptide (MDP) induces growth of mononuclear cells and induces inflammatory cell factor infection. Zharp2-1 attenuates MDP-induced small inguinal peritonitis, or ameliorates by DNBS-induced large inguinal conjunctivitis .
|
-
-
- HY-156278
-
|
|
Apoptosis
Autophagy
|
Cancer
|
|
FB49 is a highly selective inhibitor of Bcl-2-associated athanogene 3 (BAG3), with the Ki of 45 μM. FB49 inhibits the cell growth in human tumoral cells, but has no toxicity in human peripheral mononuclear cells. FB49 block cell cycle in G1 phase and to induce apoptosis as well as autophagy in medulloblastoma HD-MB03 treated cells .
|
-
-
- HY-139781
-
|
|
PD-1/PD-L1
Apoptosis
|
Cancer
|
|
PD-L1-IN-1 (Compound 10) is a potent PD-L1 inhibitor with an IC50 of 115 nM. PD-L1-IN-1 strongly binds with the PD-L1 protein and challenged it in a co-culture of PD-L1 expressing cancer cells and peripheral blood mononuclear cells enhanced antitumor immune activity of the latter. PD-L1-IN-1 significantly exhibits low cytotoxicity in healthy cells .
|
-
-
- HY-106850
-
|
AzdU; AzddU; CS-87
|
HIV
|
Infection
|
|
3′-Azido-2′,3′-dideoxyuridine (AzdU) is a nucleoside analog of Zidovudine (HY-17413). 3′-Azido-2′,3′-dideoxyuridine is a potent inhibitor of human immunodeficiency virus (HIV) replication in human peripheral blood mononuclear cells (PBMC) with limited toxicity for human bone marrow cells (BMC) . 3′-Azido-2′,3′-dideoxyuridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
-
- HY-148511
-
|
CMP-001
|
Toll-like Receptor (TLR)
IFNAR
PD-1/PD-L1
Indoleamine 2,3-Dioxygenase (IDO)
|
Cancer
|
|
Vidutolimod (CMP-001) is a virus-like particle containing a TLR9 activator . Vidutolimod induces human peripheral blood mononuclear cells to secrete IFNα, and upregulates the gene expression of CXCL10, PDL1, IDO and CD80. Vidutolimod activates TLR9, which in turn triggers plasmacytoid dendritic cell activation, production of IFNγ and TNFα, induction of CXCL10, and recruitment of antitumor T cells. Vidutolimod causes influenza-like symptoms, hypotension and tumor regression, and its activity depends on the presence of anti-Qβ antibodies. Vidutolimod modulates monocyte function, promotes CD4 T cell proliferation, and activates multiple immune cell types in an environment with anti-Qβ antibodies. Vidutolimod prolongs the survival of tumor-bearing mice. Vidutolimod is used in research related to advanced melanoma, head and neck squamous cell carcinoma, and advanced non-small cell lung cancer .
|
-
-
- HY-P4911A
-
|
|
CXCR
|
Cardiovascular Disease
|
|
SDF-1α (human) TFA is a mononuclear cells chemoattractant that can bind to CXCR4. SDF-1α plays a central role in stem cell homing, retention, survival, proliferation, cardiomyocyte repair, angiogenesis and ventricular remodelling following myocardial infarction. SDF-1α (human) TFA can be used in cardiovascular disease research .
|
-
-
- HY-W105318
-
|
PBP
|
TGF-beta/Smad
Apoptosis
|
Cancer
|
|
Pentabromophenol (PBP) is a brominated flame retardant (BFR) widely used in various consumer products to reduce the flammability of materials used in different utility items. Pentabromophenol can accelerate the degradation of transforming growth factor-β (TGF-β) receptors by promoting clathrin-mediated endocytosis, thereby inhibiting the TGF-β signaling pathway. Additionally, Pentabromophenol can also induce apoptosis in peripheral blood mononuclear cells (PBMCs) .
|
-
-
- HY-159884
-
|
|
Tim3
TNF Receptor
IFNAR
|
Cancer
|
|
MG-T-19 is an effective TIM-3 inhibitor that can suppress the interaction of TIM-3 with PtdSer, CEACAM1, and Gal-9. MG-T-19 can increase the production of tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ) in peripheral blood mononuclear cells (PBMCs) from healthy donors, and enhance the ability of PBMCs to inhibit the proliferation of Kasumi-1 cells (an acute myelogenous leukemia cell line) .
|
-
-
- HY-125726
-
|
(3'-sulfo)Galβ-Cer(d18:1/24:1); N-Nervonoyl Sulfatide; C24:1 Sulfatide
|
Nuclear Factor of activated T Cells (NFAT)
|
Inflammation/Immunology
|
|
Sulfo galactosylceramide (N-Nervonoyl Sulfatide; C24:1 Sulfatide) is a glycolipid and the major sulfolipid species in mature myelin. Sulfo galactosylceramide interacts with C-type lectins and immunoglobulin-like receptors, with the highest affinity for LMIR5. Sulfo galactosylceramide induces MCP-1 production by basophils but not mast cells, and increases NFAT activation via LMIR5. Sulfo galactosylceramide alleviates symptoms and improves survival in a mouse model of chronic relapsing-remitting experimental autoimmune encephalomyelitis (EAE), and reduces inflammatory lesions and the number of infiltrating mononuclear cells in the lumbar spinal cord of EAE mice.
|
-
-
- HY-103078
-
|
|
HIV
Reverse Transcriptase
|
Infection
|
|
I-XW-053 is a specific anti-HIV-1 capsid inhibitor (IC50=164.2 μM). By binding to the CA NTD-NTD hexamerization interface and the R173 region of CTD (Kd=66.3 μM), I-XW-053 disrupts capsid function and reduces polymerization levels. I-XW-053 effectively blocks HIV-1 uncoating, inhibits reverse transcription and early replication, and exhibits broad-spectrum activity against primary HIV-1 isolates in peripheral blood mononuclear cells. I-XW-053 can be widely used in studies related to HIV-1 infection .
|
-
-
- HY-P4911
-
|
|
CXCR
|
Cardiovascular Disease
|
|
SDF-1α (human) is a mononuclear cells chemoattractant that can bind to CXCR4. SDF-1α plays a central role in stem cell homing, retention, survival, proliferation, cardiomyocyte repair, angiogenesis and ventricular remodelling following myocardial infarction. SDF-1α (human) can be used in cardiovascular disease research .
|
-
-
- HY-P4984
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
Cancer
|
|
Toxic Shock Syndrome Toxin-1 (TSST-1) (58-78) is a T cell proliferation activator. Toxic Shock Syndrome Toxin-1 (TSST-1) (58-78) promotes the in vitro proliferation of human peripheral blood mononuclear cells (PBMC) in a dose-dependent manner. Toxic Shock Syndrome Toxin-1 (TSST-1) (58-78) can be used in research on inflammatory and immunity, as well as cancer .
|
-
-
- HY-150749A
-
|
|
IFNAR
|
Cancer
|
|
ODN D-SL03 sodium is a C class CpG oligonucleotides, and can induce stimulate PBMCs to produce high level of IFN-α. ODN D-SL03 sodium can activate human B cells, NK cells and mononuclear cells and up-regulate expression of CD80, CD86 and HLA-DR on the surface of subsets in human PBMCs. ODN D-SL03 sodium also can inhibit the growth of the tumor. ODN D-SL03 sequence: 5'-tcgcgaacgttcgccgcgttcgaacgcgg-3' .
|
-
-
- HY-P5640
-
|
|
Bacterial
Parasite
|
Infection
|
|
Tritrpticin is a porcine-derived antimicrobial peptide with properties such as membrane disruption and hemolysis. Tritrpticin disrupts the cell membranes of bacteria, fungi and Jurkat T cell leukemia cells and induces their death. Tritrpticin also enhances the efficacy of Metronidazole (HY-B0318) against *Trichomonas vaginalis*, reduces plasma endotoxin and inflammatory cytokine levels, restricts bacterial growth in blood and visceral tissues, decreases the mortality rate of septic shock in rats and enhances the therapeutic effect of ertapenem. Tritrpticin exhibits selective cytotoxicity against Jurkat T cell leukemia cells, while showing low toxicity to normal peripheral blood mononuclear cells and red blood cells, and can serve as a template for antimicrobial peptide design. Tritrpticin can be applied to research related to bacterial infections, fungal infections, trichomoniasis, septic shock and leukemia .
|
-
-
- HY-135382
-
|
|
PROTACs
IRAK
|
Inflammation/Immunology
Cancer
|
|
PROTAC IRAK4 degrader-2 (Compound 9) is a PROTAC-based IRAK4 degrader that affords potent IRAK4 degradation with a DC50 in peripheral blood mononuclear cells (PBMCs) cells of 151 nM. PROTAC IRAK4 degrader-2 induce a reduction of IRAK4 protein levels with a DC50 of 36 nM in PBMC cells. PROTAC IRAK4 degrader-2 also leads to the inhibition of multiple cytokines in PBMCs .
|
-
-
- HY-103078A
-
|
|
HIV
Reverse Transcriptase
|
Infection
|
|
I-XW-053 sodium is a specific anti-HIV-1 capsid inhibitor (IC50=164.2 μM). By binding to the CA NTD-NTD hexamerization interface and the R173 region of CTD (Kd=66.3 μM), I-XW-053 sodium disrupts capsid function and reduces polymerization levels. I-XW-053 sodium effectively blocks HIV-1 uncoating, inhibits reverse transcription and early replication, and exhibits broad-spectrum activity against primary HIV-1 isolates in peripheral blood mononuclear cells. I-XW-053 sodium can be widely used in studies related to HIV-1 infection .
|
-
-
- HY-179047
-
|
|
Toll-like Receptor (TLR)
MyD88
IKK
p38 MAPK
ERK
TNF Receptor
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
SMU-L11-R is a selective TLR7 agonist with an EC50 of 0.012 μM for human TLR7. SMU-L11-R specifically activates TLR7, recruits MyD88, and triggers MAPK/NF-κB pathways, leading to TNF-α/IL-1β/IL-6 secretion in both mouse and human peripheral blood mononuclear cells. SMU-L11-R promotes M1-like macrophage polarization. SMU-L11-R exhibits excellent synergistic anti-tumor effects with PD-L1 inhibitors by upregulating CD8 +T cells. SMU-L11-R shows potential in colorectal cancer studies .
|
-
-
- HY-118917
-
|
|
IMPDH
|
Inflammation/Immunology
|
|
VX-148 is an orally active immunosuppressant, which is a non-competitive inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor with Ki values for IMPDH Ⅱ and IMPDH Ⅰ of 6 and 14 nM respectively. VX-148 can significantly inhibit the proliferation of human peripheral blood mononuclear cells (PBMC) stimulated by T-cell mitogen (PHA) or B-cell mitogen (SPAS). VX-148 has high selectivity for lymphocytes (such as L1210, Jurkat T cells, and Raji B cells), but has no significant toxicity to non-lymphoid cells. VX-148 can inhibit antibody responses in mouse models and significantly prolong the survival time of transplanted skin in allogeneic skin transplantation models. VX-148 can be used in the research of autoimmune diseases (such as rheumatoid arthritis, psoriasis) and organ transplantation anti-rejection .
|
-
-
- HY-B0439R
-
|
Sulphadoxine (Standard)
|
Reference Standards
Parasite
HIV
Antibiotic
Endogenous Metabolite
|
Infection
|
|
Sulfadoxine (Standard) is the analytical standard of Sulfadoxine. This product is intended for research and analytical applications. Sulfadoxine(Sulphadoxine) is a long acting sulfonamide that is used, usually in combination with other agents, for respiratory, urinary tract and malarial infections. Sulfadoxine inhibits HIV replication in peripheral blood mononuclear cells.
|
-
-
- HY-148643
-
|
|
STING
|
Inflammation/Immunology
|
|
STING modulator-5 (compound 38) is a STING modulator with a pIC50 value of 9.5. STING modulator-5 antagonizes peripheral blood mononuclear cells (PBMC) with a pIC50 value of 8.1. STING modulator-5 is a antagonist of THP-1 cells, it can be used for immunological disease research .
|
-
-
- HY-W852084
-
|
|
Drug Derivative
|
Infection
Cancer
|
|
S-27609 is an imidazoquinoline with antiviral and antitumour properties. S-27609 can induce peripheral blood mononuclear cells to produce various cytokines such as interferon-α (IFN-α), tumor necrosis factor-α (TNF-α), and interleukin-1β (IL-1β). S-27609 is promising for research of viral infections (e.g., herpes virus) and tumors .
|
-
-
- HY-179009
-
|
|
NOD-like Receptor (NLR)
Interleukin Related
|
Inflammation/Immunology
|
NOD2 agonist 4 (Compound 12b) is a potent NOD2 agonist with an EC50 of 44.1 nM. NOD2 agonist 4 induces cytokine production (MCP-1, IL-6 and IL-8) in peripheral blood mononuclear cells (PBMCs), both alone and in combination with Lipopolysaccharide (LPS) (HY-D1056). NOD2 agonist 4 can be used for the studies of NOD2-targeted immunomodulator or vaccine adjuvant .
|
-
-
- HY-127023
-
|
EPA-5-HT
|
Endogenous Metabolite
FAAH
Interleukin Related
Tyrosine Hydroxylase
|
Metabolic Disease
|
|
Eicosapentaenoyl serotonin (EPA-5-HT) is an endogenous fatty acid-serotonin conjugate lipid mediator. Eicosapentaenoyl serotonin acts as an inhibitor of fatty acid amide hydrolase (FAAH). Eicosapentaenoyl serotonin suppresses IL-17 release in Concanavalin A (HY-P2149)-stimulated human peripheral blood mononuclear cells. Eicosapentaenoyl serotonin is regulated by polyunsaturated fatty acids and modulates intestinal immunity and Th17 signaling. Eicosapentaenoyl serotonin can be used for the study of inflammatory bowel disease-related mechanisms .
|
-
-
- HY-15350
-
|
LY 300046 hydrochloride
|
Reverse Transcriptase
|
Others
|
|
Trovirdine hydrochloride, a phenethylthiazolylthiourea (PETT) derivative, is an HIV reverse transcriptase (RT) non-nucleoside inhibitor (NNI). A novel computer model of the RT/NNI binding pocket revealed spatial gaps around Trovirdine hydrochloride's pyridyl ring. Docking studies suggested that replacing this planar ring with a nonplanar piperidinyl or piperazinyl ring could better occupy the binding pocket, enhancing anti-HIV activity. Synthesized heterocyclic compounds based on this modification demonstrated greater potency than Trovirdine hydrochloride, effectively inhibiting HIV replication at nanomolar concentrations without cytotoxicity in infected peripheral blood mononuclear cells .
|
-
-
- HY-P10587A
-
|
JNJ-77242113 acetate; JNJ-2113 acetate; PN-235 acetate
|
Interleukin Related
STAT
IFNAR
|
Inflammation/Immunology
|
|
Icotrokinra (JNJ-77242113) acetate is an orally available, selective antagonist of the IL-23 receptor. Icotrokinra acetate inhibits IL-23-induced STAT3 phosphorylation in peripheral blood mononuclear cells (IC50=5.6 pM) and inhibits IL-23-induced interferon IFN-γ production in NK cells with an IC50 of 18.4 pM. Icotrokinra acetate exhibits anti-inflammatory activity in a rat TNBS-induced colitis model. Icotrokinra acetate can be used in the study of psoriasis, psoriatic arthritis, and inflammatory bowel disease .
|
-
-
- HY-119337
-
|
|
Ser/Thr Protease
|
Infection
|
|
CE-2072 is an inhibitor of serine proteases neutrophil elastase and proteinase-3. CE-2072 inhibits HIV-1 production and p24 production in response to IL-18 or NaCl in infected U1 monocytic cells, reduces virus replication in infected peripheral blood mononuclear cells and blocks infection of permissive HeLa cells. CE-2072 suppresses activation of the HIV-1-inducing transcription factor NF-kB in U1 cells. CE-2072 is promising for research of HIV-1-related disease .
|
-
-
- HY-W795993
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
TJU103 is a CD4 inhibitor. TJU103 inhibits autoreactive CD4 + T cells by disrupting the function of the CD4 during activation. TJU103 decreases mononuclear cell infiltration in brain and spinal cord tissue of experimental allergic encephalomyelitis (EAE) mice model. TJU103 downregulates Th1 and Th2 cytokine levels in response to proteolipid protein epitope 139-151 (PLPe) and exhibits inhibitory effects both after the appearance of EAE symptoms and upon rechallenge with Ag. TJU103 can be used for autoimmune diseases like EAE and sclerosis (MS) research .
|
-
-
- HY-13238S1
-
|
S/GSK1349572-d3
|
Isotope-Labeled Compounds
HIV Integrase
HIV
|
Infection
|
|
Dolutegravir-d3 is the deuterium labeled Dolutegravir. Dolutegravir (S/GSK1349572) is a highly potent and orally bioavailable HIV integrase strand transfer inhibitor with an IC50 of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir (S/GSK1349572) inhibits HIV-1 viral replication with an IC50 of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC50=3.6-5.8 nM) .
|
-
-
- HY-13238S2
-
|
S/GSK1349572-d5
|
Isotope-Labeled Compounds
HIV Integrase
HIV
|
Infection
|
|
Dolutegravir-d5 is deuterium labeled Dolutegravir. Dolutegravir (S/GSK1349572) is a highly potent and orally bioavailable HIV integrase strand transfer inhibitor with an IC50 of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir (S/GSK1349572) inhibits HIV-1 viral replication with an IC50 of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC50=3.6-5.8 nM) .
|
-
-
- HY-13238R
-
|
S/GSK1349572 (Standard)
|
Reference Standards
HIV Integrase
HIV
|
Infection
|
|
Dolutegravir (Standard) is the analytical standard of Dolutegravir. This product is intended for research and analytical applications. Dolutegravir (S/GSK1349572) is a highly potent and orally bioavailable HIV integrase strand transfer inhibitor with an IC50 of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir (S/GSK1349572) inhibits HIV-1 viral replication with an IC50 of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC50=3.6-5.8 nM) .
|
-
-
- HY-177300
-
|
|
Toll-like Receptor (TLR)
HBV
IFNAR
Interleukin Related
|
Infection
Inflammation/Immunology
|
|
TLR7/8 agonist 13 is an orally active dual agonist of TLR7 (lowest effective concentrations (LEC) [hTLR7] = 1.6 μM) and TLR8 (LEC [hTLR8] = 1.6 μM). TLR7/8 agonist 13 exhibits agonistic activity against human peripheral blood mononuclear cells (hPBMCs) (LEC [hPBMC] = 0.5 μM). TLR7/8 agonist 13 induces endogenous IFNα, activating myeloid dendritic cells and monocytes toward a TH1 phenotype in mice and cynomolgus monkeys. TLR7/8 agonist 13 reduces viral load and HBV surface antigen expression in a mouse model of chronic AAV-HBV infection. TLR7/8 agonist 13 has the potential to indirectly induce IFNγ, which may promote HBV antigen-specific CD8 T cell-mediated responses. TLR7/8 agonist 13 can be used to study hepatitis B virus .
|
-
- HY-B0902AR
-
|
MF-934 hydrochloride (Standard)
|
Reference Standards
Bacterial
Antibiotic
|
Infection
|
|
Rufloxacin hydrochloride (Standard) is the analytical standard of Rufloxacin hydrochloride. This product is intended for research and analytical applications. Rufloxacin hydrochloride (MF-934 hydrochloride) is a fluoroquinolone antibacterial, inhibits B-cell differentiation in human mononuclear cells, inhibits Topo.
|
-
- HY-N1120
-
|
(+)-Triptoquinone B
|
Interleukin Related
|
Inflammation/Immunology
|
|
Triptoquinone B ((+)-Triptoquinone B), a sesquiterpene alkaloid, is an interleukin-1 inhibitor. Triptoquinone B shows potent inhibitory activities against interleukin 1α and β releases for human peripheral mononuclear cells .
|
-
- HY-N13236
-
|
|
Others
|
Inflammation/Immunology
|
|
Echinacea Purpurea Extract is an echinacea extract, and its ingredients include: Polyphenols. Echinacea Purpurea Extract is a potential anti-inflammatory agent that can inhibit LPS-induced inflammatory responses in yak peripheral blood mononuclear cells (PBMCs). .
|
-
- HY-B0439S
-
|
Sulphadoxine-d4
|
Parasite
HIV
Antibiotic
Endogenous Metabolite
|
Infection
|
|
Sulfadoxine-d4 is the deuterium labeled Sulfadoxine. Sulfadoxine(Sulphadoxine) is a long acting sulfonamide that is used, usually in combination with other agents, for respiratory, urinary tract and malarial infections. Sulfadoxine inhibits HIV replication in peripheral blood mononuclear cells.
|
-
- HY-103697B
-
|
|
HIV
Toll-like Receptor (TLR)
|
Infection
Cancer
|
|
Gardiquimod (hydrochloride) is an imidazoline TLR7/8 agonist. Gardiquimod (hydrochloride) inhibits HIV-1 infection of macrophages and activates peripheral blood mononuclear cells (PBMCs). Gardiquimod (hydrochloride) specifically activates TLR7 at concentrations below 10 μM .
|
-
- HY-NP077A
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
Phaseolus vulgaris Lectin-P is the protein form of Phytohemagglutinin before the separation and purification of Phytohemagglutinin-L (PHA-L) and PHA-E. Phaseolus vulgaris Lectin-P can be used to stimulate the proliferation of peripheral mononuclear cells, promote the production of certain cytokines and the expression of membrane surface proteins .
|
-
- HY-P1052A
-
|
|
PKC
|
Inflammation/Immunology
|
|
Myelin Basic Protein(87-99) TFA is an encephalitogenic peptide that induces basic protein-specific T cell proliferation. Myelin Basic Protein(87-99) TFA causes a Th1 polarization in peripheral blood mononuclear cells with is implicated of multiple sclerosis (MS) .
|
-
- HY-103697R
-
|
|
Toll-like Receptor (TLR)
Reference Standards
|
Cancer
|
|
Gardiquimod (Standard) is the analytical standard of Gardiquimod. This product is intended for research and analytical applications. Gardiquimod is an imidazoline TLR7/8 agonist. Gardiquimod inhibits HIV-1 infection of macrophages and activated peripheral blood mononuclear cells (PBMCs). Gardiquimod specifically activates TLR7 at concentrations below 10 μM.
|
-
- HY-153952
-
-
- HY-110216
-
|
|
CRAC Channel
|
Inflammation/Immunology
|
|
5J-4 is a potent CRAC inhibitor. 5J-4 decreases the numbers of infiltrated mononuclear cell into the CNS, and significantly decreases the population of infiltrated CD4+ population. 5J-4 reduces the symptoms and delayed the onset of EAE (experimental autoimmune encephalomyelitis) in mouse model of inflammation .
|
-
- HY-103697AR
-
|
|
Toll-like Receptor (TLR)
Reference Standards
|
Cancer
|
|
Gardiquimod (diTFA) (Standard) is the analytical standard of Gardiquimod (diTFA). This product is intended for research and analytical applications. Gardiquimod diTFA is an imidazoline TLR7/8 agonist. Gardiquimod diTFA inhibits HIV-1 infection of macrophages and activated peripheral blood mononuclear cells (PBMCs). Gardiquimod diTFA specifically activates TLR7 at concentrations below 10 μM.
|
-
- HY-N6857R
-
|
|
Reference Standards
NF-κB
|
Inflammation/Immunology
|
|
Armepavine (Standard) is the analytical standard of Armepavine. This product is intended for research and analytical applications. Armepavine, an active compound from Nelumbo nucifera, exerts not only anti-inflammatory effects on human peripheral blood mononuclear cells, but also immunosuppressive effects on T lymphocytes and on lupus nephritic mice. Armepavine inhibits TNF-α-induced MAPK and NF-κB signaling cascades .
|
-
- HY-N15307
-
|
|
Interleukin Related
TNF Receptor
|
Inflammation/Immunology
|
|
Trigraecum is a flavonoid compound found in Dracaena steudneri and Dalbergia cochinchinensis, exhibiting anti-inflammatory activity. It can inhibit the LPS (HY-D1056)-induced production of IL-1β, IL-2, GM-CSF, and TNF-α in human peripheral blood mononuclear cells. Trigraecum holds promise for research on inflammatory diseases .
|
-
- HY-118848
-
|
|
Lipoxygenase
Leukotriene Receptor
|
Inflammation/Immunology
|
|
A63162 is a specific 5-lipoxygenase (5-LOX) inhibitor. A63162 inhibits mitogen (PHA)-induced horse mononuclear cell (BMC) proliferation and inhibits Calcimycin (HY-N6687)-induced leukotriene LTB4 synthesis at the same concentration. A63162 can be used in the study of chronic obstructive pulmonary disease, arthritis and inflammatory bowel disease .
|
-
- HY-149356
-
|
|
PD-1/PD-L1
|
Cancer
|
|
PD-1/PD-L1-IN-31 is a PD-1/PD-L1 inhibitor (IC50=2.2 nM). PD-1/PD-L1-IN-31 promotes secretion of the IFN-γ, and induces immune activity of peripheral blood mononuclear cells (PBMCs) to inhibits tumor cells .
|
-
- HY-124954
-
|
|
Cannabinoid Receptor
TNF Receptor
|
Neurological Disease
Inflammation/Immunology
|
|
MN-25 (compound 4a) is an orally active indolpyridone that serves as a novel cannabinoid ligand. MN-25 has Ki of 245 nM and 11 nM for CB1 and CB2. MN-25 has CB2 agonist activity and inhibits TNF-R release in human peripheral blood mononuclear cells in vitro with an IC50 of 33 μM. MN-25 shows efficacy in a mouse acute inflammation model at oral doses up to 50 mg/kg >[1].
|
-
- HY-B1899AR
-
|
Taurodeoxycholate sodium hydrate (Standard)
|
Reference Standards
G protein-coupled Bile Acid Receptor 1
Endogenous Metabolite
|
Metabolic Disease
|
|
(E)-Methyl 4-coumarate (Standard) is the analytical standard of (E)-Methyl 4-coumarate. This product is intended for research and analytical applications. (E)-Methyl 4-coumarate (Methyl 4-hydroxycinnamate), found in several plants, such as Allium cepa or Morinda citrifolia L. leaves. (E)-Methyl 4-coumarate cooperates with Carnosic Acid in inducing apoptosis and killing acute myeloid leukemia cells, but not normal peripheral blood mononuclear cells. Antioxidant and antimicrobial activity.
|
-
- HY-150749
-
|
|
IFNAR
|
Inflammation/Immunology
Cancer
|
|
ODN D-SL03 is a C class CpG oligonucleotides, can induce stimulate PBMCs to produce high level of IFN-α. ODN D-SL03 can activate human B cells, NK cells and mononuclear cells and up-regulate expression of CD80, CD86 and HLA-DR on the surface of subsets in human PBMCs. ODN D-SL03 also can inhibit the growth of the tumor. ODN D-SL03 sequence: 5'-tcgcgaacgttcgccgcgttcgaacgcgg-3' .
|
-
- HY-168074
-
|
|
Amylases
Glycosidase
|
Metabolic Disease
Inflammation/Immunology
|
|
4″-C18 EGCG is a potent inhibitor of α-amylase and α-glucosidase with IC50 values of 3.74 and 0.81 μM, respectively. 4″-C18 EGCG inhibits carbohydrate hydrolases, reduces oxidative stress and inflammation, and exhibits antidiabetic activity. 4″-C18 EGCG also downregulates proinflammatory cytokines and is cytotoxic to primary human peripheral blood mononuclear cells (PBMCs), non-cancer cell lines 3T3-L1, and HEK 293 at 50 μM .
|
-
- HY-122566
-
|
ZINC666243
|
Toll-like Receptor (TLR)
TNF Receptor
|
Cancer
|
|
SMU127 is an agonist of the toll-like receptor 1/2 (TLR1/2) heterodimer. It induces NF-κB signaling in cells expressing human TLR2 (EC50=0.55 μM) but not cells expressing human TLR3, -4, -5, -7, or -8 when used at concentrations ranging from 0.1 to 100 μM. SMU127 induces the production of TNF-α in isolated human peripheral blood mononuclear cells (PBMCs) when used at concentrations ranging from 0.01 to 1 μM. In vivo, SMU127 (0.1 mg/animal) reduces tumor volume in a 4T1 murine mammary carcinoma model.
|
-
- HY-145473
-
|
15(S)-HETE-SAPE; 15(S)-Hydroxyeicosatetraenoic acid-SAPE; 1-Stearoyl-2-15(S)-HETE-sn-glycero-3-Phosphatidylethanolamine
|
Endogenous Metabolite
|
Metabolic Disease
|
|
1-Stearoyl-2-15(S)-HETE-sn-glycero-3-PE (15(S)-HETE-SAPE) is a phospholipid containing stearic acid (HY-B2219) at the sn-1 position and 15(S)-HETE (HY-113336) at the sn-2 position. 1-Stearoyl-2-15(S)-HETE-sn-glycero-3-PE is formed by direct oxidation of 1-stearoyl-2-arachidonoyl-sn-glycero-3-PE (SAPE) by 15-LOX in human peripheral mononuclear cells activated with the calcium ionophore A23187 (HY-N6687).
|
-
- HY-168384
-
|
|
STING
TNF Receptor
Interleukin Related
CD28
|
Inflammation/Immunology
|
|
M04 is an agonist of STING. It induces the expression of the IFN reporter gene in HEK293T cells expressing wild-type human STING, but does not induce this expression in HEK293T cells expressing the R71H-G230A-R293Q (HAQ) STING variant or in mouse RAW 264.7 cells, indicating that its activity is dependent on allelic and species variations. M04 induces the production of TNF-α, IL-10, IL-1β, and IL-12p70 in human peripheral blood mononuclear cells (PBMCs). At a concentration of 50 µM, M04 stimulates dendritic cells isolated from PBMCs to express the MHC class II cell surface receptor HLA-DR and co-stimulatory molecules CD40, CD80, and CD86, and also enhances their ability to activate T cells in an ex vivo assay. M04 can be used in research on inflammatory immune diseases .
|
-
- HY-112481
-
|
|
|
Inflammation/Immunology
|
|
IKK2-IN-5 is a selective IKK-2 inhibitor with an IC50 of 0.025 μM. IKK2-IN-5 inhibits the production of TNF-α in LPS (HY-D1056)-stimulated human peripheral blood mononuclear cells. IKK2-IN-5 exhibits extremely low cytotoxicity against human peripheral blood mononuclear cells .
|
-
- HY-NP077B
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Phaseolus vulgaris Lectin-M is a sticky protein form of lectin. Phaseolus vulgaris Lectin-M is mainly used to stimulate the proliferation of peripheral mononuclear cells, promote the production of certain cytokines and the expression of membrane surface proteins 。
|
-
- HY-P992040
-
|
16G2
|
Interleukin Related
|
Others
|
|
HAIL-12 (16G2) is anan anti-human Interleukin-12 (IL-12p70) monoclonal antibody. HAIL-12 inhibits IL-12-mediated proliferation of T cells from human peripheral blood mononuclear cells .
|
-
- HY-100870R
-
|
ABX464 (Standard)
|
HIV
Reference Standards
|
Infection
|
|
Obefazimod (Standard) is the analytical standard of Obefazimod (HY-100870). This product is intended for research and analytical applications. Obefazimod (ABX464) is a potent anti-HIV agent. Obefazimod inhibits HIV-1 replication in stimulated peripheral blood mononuclear cells (PBMCs) with an IC50 ranging between 0.1 μM and 0.5 μM.
|
-
- HY-N9566
-
|
|
Interleukin Related
TNF Receptor
IFNAR
|
Inflammation/Immunology
|
|
Isopongaflavone is an isoflavone that can be isolated from the seedpods of Tephrosia vogelii with anti-inflammatory effects. Isopongaflavone suppresses the secretion of IL-1β, IFN-γ, granulocyte macrophage-colony stimulating factor (GM-CSF) and TNF-α in LPS (HY-D1056)-stimulated peripheral blood mononuclear cells (PBMCs) .
|
-
- HY-P991851
-
|
|
Integrin
|
Inflammation/Immunology
|
|
Anti-CD11c Antibody (3.9) recognizes human CD11c. Anti-CD11c Antibody (3.9) blocks CD11c on human peripheral blood mononuclear cell-derived dendritic cells (MoDCs). Recommend Isotype Controls: Mouse IgG1 kappa, Isotype Control (HY-P99977) .
|
-
- HY-182596
-
|
|
MAPKAPK2 (MK2)
|
Inflammation/Immunology
Cancer
|
|
INHIB1X is a tetracyclic MAPKAP-K2 (MK2) inhibitor with an IC50 of 0.02 μM. INHIB1X inhibits LPS-induced TNFα release in human peripheral blood mononuclear cells (hPBMCs). INHIB1X suppresses the phosphorylation of hsp27 in Anisomycin-stimulated THP-1 cells. INHIB1X can be used for the research of inflammatory and tumor diseases .
|
-
- HY-P992058
-
|
ART-140; DNP-001; EGX-040
|
Transmembrane Glycoprotein
|
Cancer
|
|
Leukotuximab (ART-140; EGX-040) is an anti-JL1 mAb and an anti-leukemic agent. Leukotuximab targets the JL1 epitope of CD43 and exerts cytotoxic effects on JL1-positive leukemia cells. Except for thymocytes and some bone marrow mononuclear cells, Leukotuximab causes no damage to most normal tissues. Leukotuximab can be used in the research of acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome .
|
-
- HY-180320
-
|
|
LRRK2
|
Neurological Disease
|
|
Lu AF58786 is a potent and selective LRRK2 inhibitor with an IC50 of 12 nM. Lu AF58786 also exhibits inhibition activity against LRRK2 G2019S and LRRK2 A2016T with IC50s of 19 and 93 nM. Lu AF58786 inhibits phosphorylation of LRRK2, Rab10 and Rab12 in human peripheral blood mononuclear cells. Lu AF58786 can be used for parkinson’s disease research .
|
-
- HY-P10587B
-
|
JNJ-77242113 (hydrochloride); JNJ-2113 (hydrochloride); PN-235 (hydrochloride)
|
Interleukin Related
STAT
IFNAR
|
Inflammation/Immunology
|
|
Icotrokinra (JNJ-77242113) hydrochloride is an orally available, selective antagonist of the IL-23 receptor. Icotrokinra hydrochloride inhibits IL-23-induced STAT3 phosphorylation in peripheral blood mononuclear cells (IC50=5.6 pM) and inhibits IL-23-induced interferon IFN-γ production in NK cells with an IC50 of 18.4 pM. Icotrokinra hydrochloride exhibits anti-inflammatory activity in a rat TNBS-induced colitis model. Icotrokinra hydrochloride can be used in the study of psoriasis, psoriatic arthritis, and inflammatory bowel disease .
|
-
- HY-110391
-
|
VUF 2274
|
CCR
|
Neurological Disease
Inflammation/Immunology
|
|
BX-513 is a highly potent and selective CCR1 antagonist. BX-513 effectively inhibits the binding of radiolabeled MIP-1α and RANTES to CCR1, with Ki values of 40 nM and 60 nM, respectively. BX-513 suppresses MIP-1α-induced extracellular acidification, MIP-1α- and RANTES-induced intracellular calcium mobilization, as well as MIP-1α- and RANTES-induced migration of peripheral blood mononuclear cells. BX-513 can be used for the research of rheumatoid arthritis and multiple sclerosis .
|
-
- HY-125577
-
|
RU-36384
|
Interleukin Related
|
Inflammation/Immunology
|
|
VRT-18858 (RU-36384), the active metabolite of Pralnacasan (HY-19676), is a potent interleukin-1β converting enzyme (ICE) inhibitor (Ki = 1.4 nM). VRT-18858 inhibits LPS (HY-D1056)-induced IL-1β release (IC50 = 0.42 µM) and S. aureus Cowan-induced IL-1β and IL-18 release (IC50=1.3 and 2.1 µM, respectively) in human peripheral blood mononuclear cells. VRT-18858 can be used for osteoarthritis research .
|
-
- HY-D3153
-
|
|
Apoptosis
Caspase
Microtubule/Tubulin
|
Inflammation/Immunology
|
|
PbQ is a tubulin inhibitor (with an IC50 of 5 μM against goat tubulin) and a fluorescent probe for cuprous ions Cu (I). PbQ can penetrate the membrane of peripheral blood mononuclear cells, form a stable 1:1 complex with Cu + ions, and exhibits low toxicity and good biocompatibility toward macrophage cell lines. In addition, PbQ promotes tubulin degradation and disrupts the microtubule network in lung epithelial cells without affecting actin. PbQ also possesses genotoxicity by forming DNA base adducts, and it can activate caspase-3 and apoptosis-related genes, induce loss of mitochondrial membrane potential, and trigger cell apoptosis. PbQ can be used in studies related to chronic obstructive pulmonary disease .
|
-
- HY-182047
-
|
|
PD-1/PD-L1
|
Cancer
|
|
PD-1/PD-L1-IN-61 is a PD-1/PD-L1 interaction inhibitor with a human IC50 of 5.3 nM. PD-1/PD-L1-IN-61 embeds into the hydrophobic pocket at the PD-L1 dimer interface, stabilizing binding through hydrogen bonds and π-π stacking with PD-L1 residues. PD-1/PD-L1-IN-61 acts as an immune activator, enhances immune-killing activity of peripheral blood mononuclear cells against cancer cells, restores T-cell immune function, and promotes IFN-γ secretion. PD-1/PD-L1-IN-61 can be used for the research of triple-negative breast cancer .
|
-
- HY-103078R
-
|
|
Reference Standards
HIV
Reverse Transcriptase
|
Infection
|
|
I-XW-053 (Standard) is the analytical standard of I-XW-053 (HY-103078). This product is intended for research and analytical applications. I-XW-053 is a specific anti-HIV-1 capsid inhibitor (IC50=164.2 μM). By binding to the CA NTD-NTD hexamerization interface and the R173 region of CTD (Kd=66.3 μM), I-XW-053 disrupts capsid function and reduces polymerization levels. I-XW-053 effectively blocks HIV-1 uncoating, inhibits reverse transcription and early replication, and exhibits broad-spectrum activity against primary HIV-1 isolates in peripheral blood mononuclear cells. I-XW-053 can be widely used in studies related to HIV-1 infection .
|
-
- HY-175073
-
|
|
Toll-like Receptor (TLR)
Interleukin Related
|
Neurological Disease
Inflammation/Immunology
|
|
Ganglioside GT1b bovine trisodium is a trisialic acid ganglioside. Ganglioside GT1b bovine trisodium binds to botulinum toxin type A (BTxA), BTxA heavy chain, and tetanus toxin with IC50 values of 11, 0.74, and 7.2 μM, respectively. Ganglioside GT1b bovine trisodium acts as a TLR2 agonist, leading to microglial activation, increased expression of pro-inflammatory factors, and increased pain sensitivity in spinal microglia. Ganglioside GT1b bovine trisodium also reduces the production of IL-6, IL-10, IgG, IgM, and IgA in human peripheral blood mononuclear cells (PBMCs). Ganglioside GT1b bovine trisodium increases extracellular glutamate levels in neural cell models. Ganglioside GT1b bovine trisodium has potential applications in research on immune system diseases and nervous system diseases .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-D3153
-
|
|
Fluorescent Dyes
|
|
PbQ is a tubulin inhibitor (with an IC50 of 5 μM against goat tubulin) and a fluorescent probe for cuprous ions Cu (I). PbQ can penetrate the membrane of peripheral blood mononuclear cells, form a stable 1:1 complex with Cu + ions, and exhibits low toxicity and good biocompatibility toward macrophage cell lines. In addition, PbQ promotes tubulin degradation and disrupts the microtubule network in lung epithelial cells without affecting actin. PbQ also possesses genotoxicity by forming DNA base adducts, and it can activate caspase-3 and apoptosis-related genes, induce loss of mitochondrial membrane potential, and trigger cell apoptosis. PbQ can be used in studies related to chronic obstructive pulmonary disease .
|
| Cat. No. |
Product Name |
Type |
-
- HY-P3160C
-
|
|
Biochemical Assay Reagents
|
|
Fibronectin, bovine plasma is a fibronectin derived from bovine plasma. Fibronectin is an extracellular matrix protein that is upregulated and essential in many developmental processes, and also exists in the pathological progression of tissues and wound healing. Fibronectin specifically binds to a large number of molecules, including other components of the extracellular matrix, signaling molecules and cell adhesion molecules. The interaction between cells and fibronectin leads to bidirectional crosstalk, which regulates cell functions and induces cell-dependent changes in the extracellular matrix. Fibronectin, bovine plasma inhibits the production of bovine leukemia virus (BLV) p24 core protein in naturally infected bovine peripheral blood mononuclear cells .
|
-
- HY-142989
-
|
|
Biochemical Assay Reagents
|
|
1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine is a polyunsaturated phospholipid that serves as a component of lipid monolayers and small unilamellar vesicles. 1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine can be used to prepare endoplasmic reticulum-targeted liposomes (PERLs), which are composed of 1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine, l-α-phosphatidylinositol and l-α-phosphatidylserine at a molar ratio of 1.5:1.5:1:1. PERLs reduce cholesterol levels in human peripheral blood mononuclear cells (PBMCs) and decrease HIV-1 particle secretion from HIV-1-infected PBMCs. Liposomes formed from 1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine exhibit cytotoxicity against leukemia cells. 1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine is applicable to studies related to hepatitis C virus infection, HIV infection, hepatitis B virus infection and leukemia .
|
-
- HY-NP077A
-
|
|
Biochemical Assay Reagents
|
|
Phaseolus vulgaris Lectin-P is the protein form of Phytohemagglutinin before the separation and purification of Phytohemagglutinin-L (PHA-L) and PHA-E. Phaseolus vulgaris Lectin-P can be used to stimulate the proliferation of peripheral mononuclear cells, promote the production of certain cytokines and the expression of membrane surface proteins .
|
-
- HY-NP077B
-
|
|
Biochemical Assay Reagents
|
|
Phaseolus vulgaris Lectin-M is a sticky protein form of lectin. Phaseolus vulgaris Lectin-M is mainly used to stimulate the proliferation of peripheral mononuclear cells, promote the production of certain cytokines and the expression of membrane surface proteins 。
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P10587
-
|
JNJ-77242113; JNJ-2113; PN-235
|
Interleukin Related
STAT
IFNAR
|
Inflammation/Immunology
|
|
Icotrokinra (JNJ-77242113) is an orally available, selective antagonist of the IL-23 receptor. Icotrokinra inhibits IL-23-induced STAT3 phosphorylation in peripheral blood mononuclear cells (IC50=5.6 pM) and inhibits IL-23-induced interferon IFN-γ production in NK cells with an IC50 of 18.4 pM. Icotrokinra exhibits anti-inflammatory activity in a rat TNBS-induced colitis model. Icotrokinra can be used in the study of psoriasis, psoriatic arthritis, and inflammatory bowel disease .
|
-
- HY-P4911A
-
|
|
CXCR
|
Cardiovascular Disease
|
|
SDF-1α (human) TFA is a mononuclear cells chemoattractant that can bind to CXCR4. SDF-1α plays a central role in stem cell homing, retention, survival, proliferation, cardiomyocyte repair, angiogenesis and ventricular remodelling following myocardial infarction. SDF-1α (human) TFA can be used in cardiovascular disease research .
|
-
- HY-P4911
-
|
|
CXCR
|
Cardiovascular Disease
|
|
SDF-1α (human) is a mononuclear cells chemoattractant that can bind to CXCR4. SDF-1α plays a central role in stem cell homing, retention, survival, proliferation, cardiomyocyte repair, angiogenesis and ventricular remodelling following myocardial infarction. SDF-1α (human) can be used in cardiovascular disease research .
|
-
- HY-P4984
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
Cancer
|
|
Toxic Shock Syndrome Toxin-1 (TSST-1) (58-78) is a T cell proliferation activator. Toxic Shock Syndrome Toxin-1 (TSST-1) (58-78) promotes the in vitro proliferation of human peripheral blood mononuclear cells (PBMC) in a dose-dependent manner. Toxic Shock Syndrome Toxin-1 (TSST-1) (58-78) can be used in research on inflammatory and immunity, as well as cancer .
|
-
- HY-P5640
-
|
|
Bacterial
Parasite
|
Infection
|
|
Tritrpticin is a porcine-derived antimicrobial peptide with properties such as membrane disruption and hemolysis. Tritrpticin disrupts the cell membranes of bacteria, fungi and Jurkat T cell leukemia cells and induces their death. Tritrpticin also enhances the efficacy of Metronidazole (HY-B0318) against *Trichomonas vaginalis*, reduces plasma endotoxin and inflammatory cytokine levels, restricts bacterial growth in blood and visceral tissues, decreases the mortality rate of septic shock in rats and enhances the therapeutic effect of ertapenem. Tritrpticin exhibits selective cytotoxicity against Jurkat T cell leukemia cells, while showing low toxicity to normal peripheral blood mononuclear cells and red blood cells, and can serve as a template for antimicrobial peptide design. Tritrpticin can be applied to research related to bacterial infections, fungal infections, trichomoniasis, septic shock and leukemia .
|
-
- HY-P10587A
-
|
JNJ-77242113 acetate; JNJ-2113 acetate; PN-235 acetate
|
Interleukin Related
STAT
IFNAR
|
Inflammation/Immunology
|
|
Icotrokinra (JNJ-77242113) acetate is an orally available, selective antagonist of the IL-23 receptor. Icotrokinra acetate inhibits IL-23-induced STAT3 phosphorylation in peripheral blood mononuclear cells (IC50=5.6 pM) and inhibits IL-23-induced interferon IFN-γ production in NK cells with an IC50 of 18.4 pM. Icotrokinra acetate exhibits anti-inflammatory activity in a rat TNBS-induced colitis model. Icotrokinra acetate can be used in the study of psoriasis, psoriatic arthritis, and inflammatory bowel disease .
|
-
- HY-P1052
-
|
|
Peptides
|
Inflammation/Immunology
|
|
Myelin Basic Protein(87-99) is an encephalitogenic peptide that induces basic protein-specific T cell proliferation. Myelin Basic Protein(87-99) causes a Th1 polarization in peripheral blood mononuclear cells with is implicated of multiple sclerosis (MS) .
|
-
- HY-P1052A
-
|
|
PKC
|
Inflammation/Immunology
|
|
Myelin Basic Protein(87-99) TFA is an encephalitogenic peptide that induces basic protein-specific T cell proliferation. Myelin Basic Protein(87-99) TFA causes a Th1 polarization in peripheral blood mononuclear cells with is implicated of multiple sclerosis (MS) .
|
-
- HY-P10587B
-
|
JNJ-77242113 (hydrochloride); JNJ-2113 (hydrochloride); PN-235 (hydrochloride)
|
Interleukin Related
STAT
IFNAR
|
Inflammation/Immunology
|
|
Icotrokinra (JNJ-77242113) hydrochloride is an orally available, selective antagonist of the IL-23 receptor. Icotrokinra hydrochloride inhibits IL-23-induced STAT3 phosphorylation in peripheral blood mononuclear cells (IC50=5.6 pM) and inhibits IL-23-induced interferon IFN-γ production in NK cells with an IC50 of 18.4 pM. Icotrokinra hydrochloride exhibits anti-inflammatory activity in a rat TNBS-induced colitis model. Icotrokinra hydrochloride can be used in the study of psoriasis, psoriatic arthritis, and inflammatory bowel disease .
|
-
- HY-K0305
-
|
|
|
MCE Human CD34+ Cells Negative Selection Kit is designed for the isolation of CD34+ cells from human cord blood mononuclear cells (CBMC) or human peripheral blood mononuclear cells (PBMC).
|
-
- HY-K0352
-
1 Publications Verification
|
|
MCE Human CD4+ T Cells Negative Selection Kit is designed to isolate CD4+ T cells from human peripheral blood mononuclear cells (PBMCs).
|
-
- HY-K0304
-
|
|
|
MCE Human CD3+ T Cells Negative Selection Kit is designed for the isolation of CD3+ T cells from human peripheral blood mononuclear cells (PBMC).
|
-
- HY-K0351
-
|
|
|
MCE Human CD8+ T Cells Negative Selection Kit is designed to isolate CD8+ T cells from human peripheral blood mononuclear cells (PBMCs).
|
| Cat. No. |
Product Name |
Target |
Research Area |
Image |
-
- HY-P99943
-
|
KN-046
|
PD-1/PD-L1
CTLA-4
|
Cancer
|
|
Erfonrilimab (KN-046) is a monoclonal antibody targeting PD-L1/CTLA-4. Erfonrilimab blocks the PD-L1 and CTLA-4 pathways, thereby regulating T cell function. Erfonrilimab enhances the secretion of IL-2 in superantigen-stimulated peripheral blood mononuclear cells. Erfonrilimab inhibits tumor growth in xenograft and double gene knock-in mouse models. Erfonrilimab can be used in research related to a variety of advanced solid tumors, including non-small cell lung cancer and nasopharyngeal carcinoma.
|
-
(5)
-
- HY-P992040
-
|
16G2
|
Interleukin Related
|
Others
|
|
HAIL-12 (16G2) is anan anti-human Interleukin-12 (IL-12p70) monoclonal antibody. HAIL-12 inhibits IL-12-mediated proliferation of T cells from human peripheral blood mononuclear cells .
|
-
(5)
-
- HY-P991851
-
|
|
Integrin
|
Inflammation/Immunology
|
|
Anti-CD11c Antibody (3.9) recognizes human CD11c. Anti-CD11c Antibody (3.9) blocks CD11c on human peripheral blood mononuclear cell-derived dendritic cells (MoDCs). Recommend Isotype Controls: Mouse IgG1 kappa, Isotype Control (HY-P99977) .
|
-
(5)
-
- HY-P992058
-
|
ART-140; DNP-001; EGX-040
|
Transmembrane Glycoprotein
|
Cancer
|
|
Leukotuximab (ART-140; EGX-040) is an anti-JL1 mAb and an anti-leukemic agent. Leukotuximab targets the JL1 epitope of CD43 and exerts cytotoxic effects on JL1-positive leukemia cells. Except for thymocytes and some bone marrow mononuclear cells, Leukotuximab causes no damage to most normal tissues. Leukotuximab can be used in the research of acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome .
|
-
(5)
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Compare |
Product Name |
Species |
Source |
Image |
Compare Products
|
| Products |
|
| Cat. No. |
|
| Species |
|
| Source |
|
| Tag |
|
| Accession |
|
| Gene ID |
|
| Molecular Weight |
|
| Purity |
|
| Endotoxin Level |
|
| Biological Activity |
|
| Appearance |
|
| Formulation |
|
| Storage & Stability |
|
| Shipping |
|
| Free Sample |
Yes
No
|
| Size |
* This product has been "discontinued".
Optimized version of product available:
|
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-13238S1
-
|
|
|
Dolutegravir-d3 is the deuterium labeled Dolutegravir. Dolutegravir (S/GSK1349572) is a highly potent and orally bioavailable HIV integrase strand transfer inhibitor with an IC50 of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir (S/GSK1349572) inhibits HIV-1 viral replication with an IC50 of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC50=3.6-5.8 nM) .
|
-
-
- HY-13238S2
-
|
|
|
Dolutegravir-d5 is deuterium labeled Dolutegravir. Dolutegravir (S/GSK1349572) is a highly potent and orally bioavailable HIV integrase strand transfer inhibitor with an IC50 of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir (S/GSK1349572) inhibits HIV-1 viral replication with an IC50 of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC50=3.6-5.8 nM) .
|
-
-
- HY-B0439S
-
|
|
|
Sulfadoxine-d4 is the deuterium labeled Sulfadoxine. Sulfadoxine(Sulphadoxine) is a long acting sulfonamide that is used, usually in combination with other agents, for respiratory, urinary tract and malarial infections. Sulfadoxine inhibits HIV replication in peripheral blood mononuclear cells.
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-106850
-
|
AzdU; AzddU; CS-87
|
|
Azide
|
|
3′-Azido-2′,3′-dideoxyuridine (AzdU) is a nucleoside analog of Zidovudine (HY-17413). 3′-Azido-2′,3′-dideoxyuridine is a potent inhibitor of human immunodeficiency virus (HIV) replication in human peripheral blood mononuclear cells (PBMC) with limited toxicity for human bone marrow cells (BMC) . 3′-Azido-2′,3′-dideoxyuridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
| Cat. No. |
Product Name |
|
Classification |
-
- HY-142989
-
|
|
|
Phospholipids
|
|
1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine is a polyunsaturated phospholipid that serves as a component of lipid monolayers and small unilamellar vesicles. 1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine can be used to prepare endoplasmic reticulum-targeted liposomes (PERLs), which are composed of 1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine, l-α-phosphatidylinositol and l-α-phosphatidylserine at a molar ratio of 1.5:1.5:1:1. PERLs reduce cholesterol levels in human peripheral blood mononuclear cells (PBMCs) and decrease HIV-1 particle secretion from HIV-1-infected PBMCs. Liposomes formed from 1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine exhibit cytotoxicity against leukemia cells. 1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine is applicable to studies related to hepatitis C virus infection, HIV infection, hepatitis B virus infection and leukemia .
|
-
- HY-148511
-
|
CMP-001
|
|
CpG ODNs
|
|
Vidutolimod (CMP-001) is a virus-like particle containing a TLR9 activator . Vidutolimod induces human peripheral blood mononuclear cells to secrete IFNα, and upregulates the gene expression of CXCL10, PDL1, IDO and CD80. Vidutolimod activates TLR9, which in turn triggers plasmacytoid dendritic cell activation, production of IFNγ and TNFα, induction of CXCL10, and recruitment of antitumor T cells. Vidutolimod causes influenza-like symptoms, hypotension and tumor regression, and its activity depends on the presence of anti-Qβ antibodies. Vidutolimod modulates monocyte function, promotes CD4 T cell proliferation, and activates multiple immune cell types in an environment with anti-Qβ antibodies. Vidutolimod prolongs the survival of tumor-bearing mice. Vidutolimod is used in research related to advanced melanoma, head and neck squamous cell carcinoma, and advanced non-small cell lung cancer .
|
-
- HY-150749A
-
|
|
|
CpG ODNs
|
|
ODN D-SL03 sodium is a C class CpG oligonucleotides, and can induce stimulate PBMCs to produce high level of IFN-α. ODN D-SL03 sodium can activate human B cells, NK cells and mononuclear cells and up-regulate expression of CD80, CD86 and HLA-DR on the surface of subsets in human PBMCs. ODN D-SL03 sodium also can inhibit the growth of the tumor. ODN D-SL03 sequence: 5'-tcgcgaacgttcgccgcgttcgaacgcgg-3' .
|
-
- HY-150749
-
|
|
|
CpG ODNs
|
|
ODN D-SL03 is a C class CpG oligonucleotides, can induce stimulate PBMCs to produce high level of IFN-α. ODN D-SL03 can activate human B cells, NK cells and mononuclear cells and up-regulate expression of CD80, CD86 and HLA-DR on the surface of subsets in human PBMCs. ODN D-SL03 also can inhibit the growth of the tumor. ODN D-SL03 sequence: 5'-tcgcgaacgttcgccgcgttcgaacgcgg-3' .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: